Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Neuroendocrine carcinoma of the urinary bladder (NCUB) is rare, accounting for < 1% of bladder cancer cases, with scarce reported data available.

We retrospectively reviewed the data from patients with NCUB treated at French institutions. The objectives were to describe the patient characteristics, treatments received, and outcomes (ie, disease-free survival [DFS], progression-free survival, overall survival [OS]) and investigate the prognostic factors.

From 1997 to 2017, we included 236 patients, 173 with early-stage NCUB and 63 with advanced-stage NCUB. For those with early-stage disease, the median DFS was better for the patients who had received cisplatin-based chemotherapy compared with carboplatin (hazard ratio [HR], 1.95; 95% confidence interval [CI], 1.1-3.46), with no difference found between the neoadjuvant and adjuvant settings (HR, 1.1; 95% CI, 0.61-1.97). The median OS was 36 months (95% CI, 29-43 months) for stage I and II, 26 months (95% CI, 18 months to not reached) for stage IIIA, 16 months (95% CI, 12-21 months) for stage IIIB. The HR for stage IIIB compared with stage I/II was 2.6 (95% CI, 1.5-4.4). The DFS at 6 months was associated with OS (HR, 7.8; 95% CI, 4.1-15.0). For patients with metastases at diagnosis who had received chemotherapy, the median progression-free survival was 9 months (95% CI, 8-11) for first-line cisplatin and 6 months (95% CI, 4-13 months) for carboplatin; the median OS was 13 months (95% CI, 9-15 months). A high-risk Bajorin score (HR, 11.5; 95% CI, 1.2-112.6) and the use of carboplatin (HR, 2.26; 95% CI, 1.03-4.96) were associated with worse outcomes.

In early-stage disease, a shorter DFS was associated with worse OS, and the use of cisplatin was associated with better OS. For the patients with metastases at diagnosis, a high-risk Bajorin score and the use of carboplatin were associated with worse outcomes.

Clinical genitourinary cancer. 2019 Dec 05 [Epub ahead of print]

Marine Sroussi, Reza Elaidi, Aude Fléchon, Marianne Lorcet, Delphine Borchiellini, Magalie P Tardy, Gwenaelle Gravis, Mathilde Guérin, Brigitte Laguerre, Florian Estrade, Rémi Delva, Phillipe Barthélémy, Yohann Loriot, Pernelle Lavaud, Thierry Lebret, Yann Neuzillet, Nicolas Penel, Nadine Houede, Damien Pouessel, Benoit Rousseau, Elodie Mussat, Marine Gross-Goupil, Stéphane Culine, Hélène Gauthier, Aurélien Gobert, Morgan Roupret, Olivier Huillard, Sophie Tartas, Camélia Radulescu, Yves Allory, Stéphane Oudard

Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France. Electronic address: ., Association pour la Recherche et les Thérapeutiques Innovantes en Cancérologie, Paris, France., Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Department of Medical Oncology, Centre Antoine Lacassagne, Cote d'Azur University, Nice, France., Department of Medical Oncology, Institut Paoli-Calmettes Aix-Marseille University, Inserm, Centre National de la Recherche Scientifique, Centre de Recherche en Cancérologie de Marseille, Marseille, France., Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Department of Medical Oncology, Centre Paul Papin, Angers, France., Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France., Department of Urology, Hôpital Foch, University of Paris Saclay, Suresnes, France., Department of Medical Oncology, Centre Oscar Lambret, Lille University, Lille, France., Department of Medical Oncology, de Centre Hospitalier Universitaire Nimes, Montpellier University, Nimes, France., Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France., Department of Medical Oncology, Hôpital Henri Mondor, Paris, France., Department of Medical Oncology, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France., Department of Medical Oncology, Hôpital St Louis, University of Paris Diderot, Paris, France., Department of Medical Oncology, Hôpital Pitié-Salpêtrière, Paris, France., GRC no5, Oncotype-URO, Assistance Publique - Hôpitaux de Paris, Sorbonne University, and Department of Urology, Hôpital Pitié-Salpêtrière, Paris, France., Department of Medical Oncology, Hôpital Cochin, Paris, France., Department of Medical Oncology, Centre Hospitalier Universitaire Lyon, Lyon, France., Department of Pathology, Hôpital Foch, Suresnes, France., Department of Pathology, Hôpital Foch, Suresnes, France; Department of Pathology, Institut Curie, Saint-Cloud, France., Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France; Association pour la Recherche et les Thérapeutiques Innovantes en Cancérologie, Paris, France; University René Descartes, Paris, France.